@FiercePharma: $GSK rehires former China government affairs director Shi. FiercePharmaAsia story | Follow @FiercePharma
@EricPFierce: ICYMI: #FDA may add Baxter #saline Mexico plant to US supply. Now if Baxter can just quit having to recall saline. More | Follow @EricPFierce
@CarlyHFierce: What was summer before I covered takeover battles? | Follow @CarlyHFierce
> Daiichi Sankyo's new blood thinner Lixiana has been recommended for a second indication in England to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation. Story
> Taro Pharmaceuticals ($TARO) reported increased revenues for the second quarter. Release
> GlaxoSmithKline ($GSK) and Theravance ($THRX) on Thursday announced the approval in Canada of Breo Ellipta for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease. Release
Medical Device News
@FierceMedDev: Updated w/ info from $MDT: Medtronic recalls CoreValve TAVR component due to presence of particulate matter. Story | Follow @FierceMedDev
@VarunSaxena2: FDA issues warning on heart pump safety issues: strokes, blood clots and bleeding. Article | Follow @VarunSaxena2
@EmilyWFierce: ICYMI from FiercePharma: British watchdog cracks down on Pfizer for huge price hikes on epilepsy drug. Story | Follow @EmilyWFierce
> TAVR maker JenaValve receives $26.5M to fund U.S. studies. Report
> DexCom ups 2015 guidance but doesn't aim for profit; plans next-gen launches this year, in 2017. Story
> Cardinal scores $1B DOD contract as dealmaking delivers growth. Article
Biotech News
@FierceBiotech: Pfizer takes the lead in another hot immuno-oncology contest. Report | Follow @FierceBiotech
@JohnCFierce: Tick tock--Fierce 15 noms deadline is approaching. More | Follow @JohnCFierce
@DamianFierce: Probably the best thing about having lots of money is how it turns itself into even more money. Story | Follow @DamianFierce
> Decimated by clinical failure, Xoma turns to plan B. More
> NantKwest's record-setting IPO heaps another billion on Soon-Shiong's fortune. Story
> Sanofi deepens its Evotec ties with a $330M diabetes deal. Article